Resistance of HIV to both protease inhibitors and reverse transcriptase inhibitors has become a huge problem for the clinical management of AIDS, stimulating the search for inhibitors of these enzymes that are not made clinically useless by viral evolution.

Last week, Tibotec N.V. reported that its approach using viral vitality screening and structure-based drug design has resulted in a series of compounds that are both highly potent against viruses and effective against protease enzymes that have already become resistant to clinically used protease inhibitors.